» Articles » PMID: 37742037

EBUS-GS with the GeneXpert MTB/RIF Assay for Diagnosis of Mycobacterium Tuberculosis Infection of Isolated Pulmonary Nodules

Overview
Journal Eur J Med Res
Publisher Biomed Central
Specialty General Medicine
Date 2023 Sep 23
PMID 37742037
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Investigate the use of endobronchial ultrasonography with a guide sheath (EBUS-GS) combined with Gene Xpert MTB/RIF (Xpert) for diagnosis of Mycobacterium tuberculosis (MTB) infection in isolated pulmonary nodules.

Methods: Patients who had isolated pulmonary nodules and unknown diagnoses at our institution from October 2020 to December 2021 were prospectively examined using EBUS-GS and Xpert. The diagnostic values of using EBUS-GS or bronchoalveolar lavage fluid (BALF) with acid-fast staining, MGIT 960 culture, pathological examination, and Xpert for isolated pulmonary nodules caused by MTB infection were compared using receiver operating characteristic (ROC) analysis.

Results: There were 135 patients, 64 with isolated pulmonary tuberculomas and 71 with non-tuberculous lesions. The sensitivity of EBUS-GS with Xpert was significantly higher than BALF with Xpert (57.81% vs. 34.78%, P = 0.017). Use of EBUS-GS with Xpert and MGIT 960 culture further increased the sensitivity to 62.50% (95%CI 50.64-74.36) and increased the specificity to 100%. The AUC values of BALF with MGIT 960 culture was 0.663(95%CI 0.543-0.783) and BALF with Xpert was 0.674 (95%CI 0.556-0.792). The AUC values of EBUS-GS with MGIT 960 culture was 0.680 (95%CI 0.554-0.743), with pathological examination was 0.713 (95%CI 0.573-0.760), and with Xpert was 0.789 (95%CI 0.655-0.829).

Conclusion: Use of EBUS-GS with Xpert had high sensitivity and specificity in the diagnosis of isolated pulmonary tuberculoma. This method has significant potential for use in clinical practice.

Citing Articles

Enhancing the Accuracy of Peripheral Pulmonary Tuberculosis Diagnosis: A Comparative Evaluation of CapitalBio Nucleic Acid Detection Test and Isothermal RNA Amplification Assay Using Endobronchial Ultrasonography with Guide Sheath.

Zhou L, Yong Y, Li H, Hu Q Infect Drug Resist. 2024; 17:4685-4693.

PMID: 39473911 PMC: 11520711. DOI: 10.2147/IDR.S476732.


Diagnostic value of the Xpert MTB/RIF assay combined with endobronchial ultrasonography with a guide sheath for peripheral nodular pulmonary tuberculosis.

Zhou L, Yong Y, Ran X, Li H, Hu Q BMC Infect Dis. 2024; 24(1):1017.

PMID: 39304805 PMC: 11414085. DOI: 10.1186/s12879-024-09901-0.


Enhanced diagnosis of pulmonary tuberculosis through nucleotide MALDI-TOF MS analysis of BALF: a retrospective clinical study.

Jiang L, Xin J, Liang L, Xia M, Li J, Tong J Sci Rep. 2024; 14(1):18416.

PMID: 39117658 PMC: 11310484. DOI: 10.1038/s41598-024-66178-8.


Bronchoscopic Strategies to Improve Diagnostic Yield in Pulmonary Tuberculosis Patients.

Kim S, Eom J, Mok J Tuberc Respir Dis (Seoul). 2024; 87(3):302-308.

PMID: 38547859 PMC: 11222098. DOI: 10.4046/trd.2024.0020.

References
1.
Ma L, Fang Y, Zhang T, Xue P, Bo L, Liu W . Comparison in efficacy and safety of forceps biopsy for peripheral lung lesions guided by endobronchial ultrasound-guided sheath (EBUS-GS) and electromagnetic navigation bronchoscopy combined with EBUS (ENB-EBUS). Am J Transl Res. 2020; 12(8):4604-4611. PMC: 7476157. View

2.
Stellmacher F, Perner S . [Overview: granulomatous diseases of the lung]. Pathologe. 2021; 42(1):64-70. DOI: 10.1007/s00292-020-00893-7. View

3.
Alshoabi S, Almas K, Aldofri S, Hamid A, Alhazmi F, Alsharif W . The Diagnostic Deceiver: Radiological Pictorial Review of Tuberculosis. Diagnostics (Basel). 2022; 12(2). PMC: 8870832. DOI: 10.3390/diagnostics12020306. View

4.
Wang W, Yu L, Wang Y, Zhang Q, Chi C, Zhan P . Radial EBUS versus CT-guided needle biopsy for evaluation of solitary pulmonary nodules. Oncotarget. 2018; 9(19):15122-15131. PMC: 5871103. DOI: 10.18632/oncotarget.23952. View

5.
Ren H, Zhang X, Zhang K, Li T, Gao B, Chen Z . Endobronchial Ultrasound Combined with Clinical Data for Predicting Malignant Peripheral Pulmonary Lesions. Cancer Manag Res. 2020; 12:9837-9844. PMC: 7552913. DOI: 10.2147/CMAR.S251683. View